Thierry HULOT

Bio

Thierry Hulot, 58, has degrees in pharmacy and drug metabolism (René Descartes University and Paris Sud University). He also holds an MBA from Ashridge University (UK). He began his career in 1989 as a biopharmaceutical researcher at the Delagrange laboratory. In 1992, he joined Synthélabo Recherche as project manager in clinical pharmacokinetics. Thierry Hulot joined the Merck Group in 1995, where he held various R&D positions in France and Germany. In 2007, he continued his activity in Switzerland at Merck Serono, after the acquisition of Serono by the Merck Group. He created the Project Management function within the new company. He then headed the office of the President of Merck Serono until 2012, before creating the Biosimilars business in 2013. In October 2013, he was appointed Director of Industrial and Global Supply Activities. Since February 1, 2017, Thierry Hulot has been Chairman and Chief Executive Officer of Merck in France (with 3 business areas: health, life sciences, electronics). He is also Managing Director of the Merck Biopharma Division in France. Thierry Hulot has been an administrator of Leem since 2017. From October 2018 to July 2019, he led the CSR Commission. He was also Head of European laboratories represented in Leem. Thierry Hulot has been president of Leem since 5 July 2022, for a 2-year term.